导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.73% | 4076/4773 |
| 近一周 | -0.06% | 474/5458 |
| 近一月 | 0.06% | 814/5421 |
| 近一季 | -5.99% | 3047/5205 |
| 近半年 | -16.65% | 4167/4920 |
| 近一年 | -1.66% | 2969/4361 |
| 近两年 | 34.55% | 2143/2954 |
| 近三年 | 3.08% | 1887/2253 |
| 成立以来 | 112.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.28% 3588/4961 |
-1.02% 3330/5312 |
- - |
- - |
| 2025 | 27.58% 1549/4813 |
-3.91% 3104/3635 |
11.51% 177/4076 |
7.25% 3465/4524 |
11.03% 175/4813 |
| 2024 | 4.34% 1882/3463 |
-8.36% 2223/2808 |
2.62% 331/3014 |
11.16% 2546/3129 |
-0.19% 1340/3463 |
| 2023 | -20.26% 1869/2656 |
-6.51% 2167/2280 |
2.05% 175/2385 |
-9.43% 1823/2515 |
-7.72% 2196/2655 |
| 2022 | -24.00% 1182/2207 |
-22.11% 1684/1919 |
6.35% 717/2016 |
-5.60% 82/2113 |
-2.81% 1815/2208 |
| 2021 | 18.64% 206/1822 |
-17.75% 1203/1255 |
10.76% 437/1330 |
9.97% 127/1466 |
18.42% 34/1822 |
| 2020 | 75.90% 52/1250 |
0.66% 158/1028 |
14.58% 546/1067 |
27.86% 20/1164 |
19.29% 77/1184 |
| 2019 | 23.48% 627/1092 |
28.34% 316/754 |
-8.60% 600/804 |
5.44% 149/850 |
-0.16% 887/918 |
| 2018 | -26.60% 387/834 |
- - |
- - |
- - |
-13.03% 504/691 |
| 2017 | -15.98% 566/714 |
- - |
- - |
- - |
- - |
| 2016 | -20.89% 449/605 |
- - |
- - |
- - |
- - |
| 2015 | 36.27% 55/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 前海开源中证军工指数A VS. 长安沪深300非周期A(740101) |